← Leaderboards
Joseph Anthoney Vetro
University Of Nebraska Medical Center
$4,871,710
Attributed
$4,871,710
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $996.7K · FY2007–20$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,871,710 · 7
By mechanism
R01$3,476,160 · 2
P20$669,990 · 3
R21$400,575 · 1
R41$324,985 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Serguei V Vinogradov$4,193,151
- Alexander V Kabanov$28,176,125
- Tatiana K Bronich$14,219,791
- Elena Batrakova$5,302,306
- Ram I Mahato$10,713,899
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelModificationProteinsUnited States National Institutes Of HealthSurfaceAttenuatedLeadPublic HealthMissionIn VitroClinical TrialsAgonistC5a Anaphylatoxin ReceptorPathogenAntigen-Presenting CellsInfectionCell SurfaceCellsStructureTumorCaliberDoseNanoparticleCancer Therapy
Grant awards (15)
Host-Directed Immunotherapy: A "One Health" Approach$620,473
R01 · FY2020 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,250
R01 · FY2020 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,250
R01 · FY2019 · AI · contact PI
Host-Directed Immunotherapy: A "One Health" Approach$342,748
R01 · FY2019 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,250
R01 · FY2018 · AI · contact PI
Host-Directed Immunotherapy: A "One Health" Approach$355,373
R01 · FY2018 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,192
R01 · FY2017 · AI · contact PI
Host-Directed Immunotherapy: A "One Health" Approach$263,848
R01 · FY2017 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$388,776
R01 · FY2016 · AI · contact PI
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer$324,985
R41 · FY2016 · TR · contact PI
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE$223,081
P20 · FY2011 · RR · contact PI
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE$225,335
P20 · FY2010 · RR · contact PI
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE$221,574
P20 · FY2009 · RR · contact PI
Development of Targeted Nanogels for siRNA Delivery to Tumor Vasculature$180,075
R21 · FY2008 · EB · contact PI
Development of Targeted Nanogels for siRNA Delivery to Tumor Vasculature$220,500
R21 · FY2007 · EB · contact PI